BEAM Beam Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BEAM

Price (delayed)

$23.13

Market cap

$1.89B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.72

Enterprise value

$1.62B

Beam Therapeutics is a biotechnology company committed to establishing the leading, fully integrated platform for precision genetic medicines. To achieve this vision, Beam has assembled a platform that includes a ...

Highlights
The EPS has surged by 59% since the previous quarter and by 58% year-on-year
The net income has surged by 58% since the previous quarter and by 54% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://beamtx.com
Peers: OMER OMGA

Key stats

What are the main financial stats of BEAM
Market
Shares outstanding
81.66M
Market cap
$1.89B
Enterprise value
$1.62B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.92
Price to sales (P/S)
4.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.28
Earnings
Revenue
$377.71M
EBIT
-$131.16M
EBITDA
-$111.15M
Free cash flow
-$182.93M
Per share
EPS
-$1.72
Free cash flow per share
-$2.37
Book value per share
$12.04
Revenue per share
$4.9
TBVPS
$18.92
Balance sheet
Total assets
$1.46B
Total liabilities
$478.39M
Debt
$172.69M
Equity
$981.33M
Working capital
$1.01B
Liquidity
Debt to equity
0.18
Current ratio
5.89
Quick ratio
5.83
Net debt/EBITDA
2.45
Margins
EBITDA margin
-29.4%
Gross margin
100%
Net margin
-35.1%
Operating margin
-46.7%
Efficiency
Return on assets
-9.8%
Return on equity
-15.9%
Return on invested capital
-12.6%
Return on capital employed
-10.5%
Return on sales
-34.7%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BEAM stock price

How has the Beam Therapeutics stock price performed over time
Intraday
1.8%
1 week
8.19%
1 month
-22.07%
1 year
-26.9%
YTD
-15.03%
QTD
-29.99%

Financial performance

How have Beam Therapeutics's revenue and profit performed over time
Revenue
$377.71M
Gross profit
$377.71M
Operating income
-$176.49M
Net income
-$132.53M
Gross margin
100%
Net margin
-35.1%
The net margin has soared by 93% YoY and by 91% from the previous quarter
Beam Therapeutics's operating margin has surged by 92% YoY and by 90% QoQ
The net income has surged by 58% since the previous quarter and by 54% year-on-year
Beam Therapeutics's operating income has surged by 56% QoQ and by 48% YoY

Growth

What is Beam Therapeutics's growth rate over time

Valuation

What is Beam Therapeutics stock price valuation
P/E
N/A
P/B
1.92
P/S
4.72
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.28
The EPS has surged by 59% since the previous quarter and by 58% year-on-year
The price to book (P/B) is 70% lower than the 5-year quarterly average of 6.4 and 29% lower than the last 4 quarters average of 2.7
BEAM's equity is up by 34% year-on-year and by 26% since the previous quarter
BEAM's price to sales (P/S) is 100% lower than its 5-year quarterly average of 52078.6 and 79% lower than its last 4 quarters average of 22.0

Efficiency

How efficient is Beam Therapeutics business performance
The return on sales has surged by 93% year-on-year and by 91% since the previous quarter
The ROE has soared by 61% QoQ and by 58% YoY
The company's return on assets has surged by 58% QoQ and by 53% YoY
BEAM's ROIC has soared by 57% QoQ and by 52% YoY

Dividends

What is BEAM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BEAM.

Financial health

How did Beam Therapeutics financials performed over time
BEAM's quick ratio is up by 25% since the previous quarter and by 19% year-on-year
BEAM's current ratio is up by 25% QoQ and by 20% YoY
The debt is 82% less than the equity
BEAM's equity is up by 34% year-on-year and by 26% since the previous quarter
The company's debt to equity fell by 25% YoY and by 18% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.